287 related articles for article (PubMed ID: 24067534)
21. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
Smith MA; Mohammad RA
Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
[TBL] [Abstract][Full Text] [Related]
22. Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis.
Haanstra KG; Hofman SO; Lopes Estêvão DM; Blezer EL; Bauer J; Yang LL; Wyant T; Csizmadia V; 't Hart BA; Fedyk ER
J Immunol; 2013 Mar; 190(5):1961-73. PubMed ID: 23365083
[TBL] [Abstract][Full Text] [Related]
23. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
[TBL] [Abstract][Full Text] [Related]
24. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
Jovani M; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
[TBL] [Abstract][Full Text] [Related]
25. Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.
Boden EK; Kongala R; Hindmarch DC; Shows DM; Juarez JG; Lord JD
Inflamm Bowel Dis; 2024 May; 30(5):704-717. PubMed ID: 37837660
[TBL] [Abstract][Full Text] [Related]
26. Baseline levels of dynamic CD4
Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
[TBL] [Abstract][Full Text] [Related]
27. High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
Harrer A; Pilz G; Wipfler P; Oppermann K; Sellner J; Hitzl W; Haschke-Becher E; Afazel S; Rispens T; van der Kleij D; Trinka E; Kraus J
Clin Exp Immunol; 2015 Jun; 180(3):383-92. PubMed ID: 25603898
[TBL] [Abstract][Full Text] [Related]
28. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
30. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
31. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
[TBL] [Abstract][Full Text] [Related]
32. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.
Wyant T; Leach T; Sankoh S; Wang Y; Paolino J; Pasetti MF; Feagan BG; Parikh A
Gut; 2015 Jan; 64(1):77-83. PubMed ID: 24763133
[TBL] [Abstract][Full Text] [Related]
33. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Saruta M; Papadakis KA
Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
[TBL] [Abstract][Full Text] [Related]
34. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
Rosario M; Dirks NL; Milch C; Parikh A; Bargfrede M; Wyant T; Fedyk E; Fox I
Clin Pharmacokinet; 2017 Nov; 56(11):1287-1301. PubMed ID: 28523450
[TBL] [Abstract][Full Text] [Related]
35. Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
Dulai PS; Mosli M; Khanna R; Levesque BG; Sandborn WJ; Feagan BG
Pharmacotherapy; 2015 Apr; 35(4):412-23. PubMed ID: 25884529
[TBL] [Abstract][Full Text] [Related]
36. Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.
Cherry LN; Yunker NS; Lambert ER; Vaughan D; Lowe DK
Ther Adv Chronic Dis; 2015 Sep; 6(5):224-33. PubMed ID: 26336591
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab.
Wyant T; Estevam J; Yang L; Rosario M
Cytometry B Clin Cytom; 2016 Mar; 90(2):168-76. PubMed ID: 25908521
[TBL] [Abstract][Full Text] [Related]
38. Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
Rosario M; Wyant T; Leach T; Sankoh S; Scholz C; Parikh A; Fox I; Feagan BG
Clin Drug Investig; 2016 Nov; 36(11):913-923. PubMed ID: 27422740
[TBL] [Abstract][Full Text] [Related]
39. Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles.
Fuchs F; Schillinger D; Atreya R; Hirschmann S; Fischer S; Neufert C; Atreya I; Neurath MF; Zundler S
Front Immunol; 2017; 8():764. PubMed ID: 28717358
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
Gubatan J; Rubin SJS; Bai L; Haileselassie Y; Levitte S; Balabanis T; Patel A; Sharma A; Sinha SR; Habtezion A
J Crohns Colitis; 2021 Dec; 15(12):1980-1990. PubMed ID: 34180967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
